{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T04:08:09Z","timestamp":1743307689686,"version":"3.40.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19H05556","20K09517"],"award-info":[{"award-number":["19H05556","20K09517"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-95844-8","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T13:48:56Z","timestamp":1743256136000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multicenter, international, retrospective study of prognostic factors for Ra223"],"prefix":"10.1038","volume":"15","author":[{"given":"Takuya","family":"Oishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao-Lun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiomi","family":"Hatayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daichi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuma","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jotaro","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppei","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Li","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Hsiang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Ta","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Jen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikara","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0026-4079","authenticated-orcid":false,"given":"Shingo","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"95844_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford, P. et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: Treatment of relapsing and metastatic prostate cancer. Eur. Urol. 79, 263\u2013282. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.046 (2021).","journal-title":"Eur. Urol."},{"key":"95844_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/iju.15449","volume":"31","author":"L Blas","year":"2024","unstructured":"Blas, L. et al. Survival beyond Cabazitaxel for metastatic castration-resistant prostate cancer. Int. J. Urol. 31, 829\u2013831. https:\/\/doi.org\/10.1111\/iju.15449 (2024).","journal-title":"Int. J. Urol."},{"key":"95844_CR3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/iju.15499","volume":"31","author":"K Hashimoto","year":"2024","unstructured":"Hashimoto, K. et al. Current issues and management consensus of advanced prostate cancer: Report of the advanced prostate cancer consensus Conference-JAPAN 2023. Int. J. Urol. 31, 975\u2013985. https:\/\/doi.org\/10.1111\/iju.15499 (2024).","journal-title":"Int. J. Urol."},{"key":"95844_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15545","author":"Y Kohjimoto","year":"2024","unstructured":"Kohjimoto, Y. et al. Japanese clinical practice guidelines for prostate cancer 2023. Int. J. Urol. https:\/\/doi.org\/10.1111\/iju.15545 (2024).","journal-title":"Int. J. Urol."},{"key":"95844_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15540","author":"Q Sun","year":"2024","unstructured":"Sun, Q. et al. Local treatment benefits patients with oligometastatic prostate cancer: A systematic review and meta-analysis. Int. J. Urol. https:\/\/doi.org\/10.1111\/iju.15540 (2024).","journal-title":"Int. J. Urol."},{"key":"95844_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15546","author":"F Urabe","year":"2024","unstructured":"Urabe, F. et al. Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study. Int. J. Urol. https:\/\/doi.org\/10.1111\/iju.15546 (2024).","journal-title":"Int. J. Urol."},{"key":"95844_CR7","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/iju.15498","volume":"31","author":"H Watanabe","year":"2024","unstructured":"Watanabe, H. et al. Prognostic outcomes in Japanese patients with metastatic castration-sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor. Int. J. Urol. 31, 986\u2013993. https:\/\/doi.org\/10.1111\/iju.15498 (2024).","journal-title":"Int. J. Urol."},{"key":"95844_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213\u2013223. https:\/\/doi.org\/10.1056\/NEJMoa1213755 (2013).","journal-title":"N. Engl. J. Med."},{"key":"95844_CR9","doi-asserted-by":"publisher","unstructured":"Saad, F. et al. Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). Can. Urol. Assoc. J. 15, E81\u2013E90 https:\/\/doi.org\/10.5489\/cuaj.7074 (2021).","DOI":"10.5489\/cuaj.7074"},{"key":"95844_CR10","doi-asserted-by":"publisher","first-page":"100311","DOI":"10.1016\/j.jbo.2020.100311","volume":"25","author":"JE Brown","year":"2020","unstructured":"Brown, J. E. et al. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. J. Bone Oncol. 25, 100311. https:\/\/doi.org\/10.1016\/j.jbo.2020.100311 (2020).","journal-title":"J. Bone Oncol."},{"key":"95844_CR11","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad, F. et al. Long-term efficacy of Zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl. Cancer Inst. 96, 879\u2013882. https:\/\/doi.org\/10.1093\/jnci\/djh141 (2004).","journal-title":"J. Natl. Cancer Inst."},{"key":"95844_CR12","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/s0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James, N. D. et al. Addition of docetaxel, Zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387, 1163\u20131177. https:\/\/doi.org\/10.1016\/s0140-6736(15)01037-5 (2016).","journal-title":"Lancet"},{"key":"95844_CR13","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/iju.15259","volume":"30","author":"L Blas","year":"2023","unstructured":"Blas, L. et al. Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment. Int. J. Urol. 30, 1029\u20131034. https:\/\/doi.org\/10.1111\/iju.15259 (2023).","journal-title":"Int. J. Urol."},{"key":"95844_CR14","doi-asserted-by":"publisher","first-page":"9307","DOI":"10.2147\/cmar.S213051","volume":"11","author":"S Cheng","year":"2019","unstructured":"Cheng, S. et al. Population-based analysis of the use of radium-223 for bone-metastatic castration-resistant prostate cancer in Ontario, and of factors associated with treatment completion and outcome. Cancer Manag Res. 11, 9307\u20139319. https:\/\/doi.org\/10.2147\/cmar.S213051 (2019).","journal-title":"Cancer Manag Res."},{"key":"95844_CR15","doi-asserted-by":"publisher","first-page":"8579","DOI":"10.1002\/cam4.3459","volume":"9","author":"K Hashimoto","year":"2020","unstructured":"Hashimoto, K. et al. Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer. Cancer Med. 9, 8579\u20138588. https:\/\/doi.org\/10.1002\/cam4.3459 (2020).","journal-title":"Cancer Med."},{"key":"95844_CR16","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s10147-020-01850-3","volume":"26","author":"H Uemura","year":"2021","unstructured":"Uemura, H. et al. Real-world safety and effectiveness of radium-223 in Japanese patients with castration-resistant prostate cancer (CRPC) and bone metastasis: Exploratory analysis, based on the results of post-marketing surveillance, according to prior chemotherapy status and in patients without concomitant use of second-generation androgen-receptor axis-targeted agents. Int. J. Clin. Oncol. 26, 753\u2013763. https:\/\/doi.org\/10.1007\/s10147-020-01850-3 (2021).","journal-title":"Int. J. Clin. Oncol."},{"key":"95844_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41391-020-00271-7","volume":"24","author":"RR McKay","year":"2021","unstructured":"McKay, R. R. et al. Treatment of metastatic castration resistant prostate cancer with radium-223: A retrospective study at a US tertiary oncology center. Prostate Cancer Prostatic Dis. 24, 210\u2013219. https:\/\/doi.org\/10.1038\/s41391-020-00271-7 (2021).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"95844_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/iju.15078","volume":"30","author":"T Matsumoto","year":"2023","unstructured":"Matsumoto, T. et al. Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study. Int. J. Urol. 30, 139\u2013146. https:\/\/doi.org\/10.1111\/iju.15078 (2023).","journal-title":"Int. J. Urol."},{"key":"95844_CR19","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2217\/fon-2020-0039","volume":"16","author":"MC Kuppen","year":"2020","unstructured":"Kuppen, M. C. et al. Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. Future Oncol. 16, 1371\u20131384. https:\/\/doi.org\/10.2217\/fon-2020-0039 (2020).","journal-title":"Future Oncol."},{"key":"95844_CR20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/mnm.0000000000001325","volume":"42","author":"P Jarvis","year":"2021","unstructured":"Jarvis, P., Ho, A. & Sundram, F. Radium-223 therapy for metastatic castration-resistant prostate cancer: Survival benefit when used earlier in the treatment pathway. Nucl. Med. Commun. 42, 332\u2013336. https:\/\/doi.org\/10.1097\/mnm.0000000000001325 (2021).","journal-title":"Nucl. Med. Commun."},{"key":"95844_CR21","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1007\/s00259-019-4261-y","volume":"46","author":"S Dizdarevic","year":"2019","unstructured":"Dizdarevic, S. et al. Interim analysis of the REASSURE (Radium-223 alpha emitter agent in non-intervention safety study in mCRPC population for long-teRm Evaluation) study: Patient characteristics and safety according to prior use of chemotherapy in routine clinical practice. Eur. J. Nucl. Med. Mol. Imaging. 46, 1102\u20131110. https:\/\/doi.org\/10.1007\/s00259-019-4261-y (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"95844_CR22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s10147-020-01776-w","volume":"26","author":"Y Yamamoto","year":"2021","unstructured":"Yamamoto, Y. et al. Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases. Int. J. Clin. Oncol. 26, 192\u2013198. https:\/\/doi.org\/10.1007\/s10147-020-01776-w (2021).","journal-title":"Int. J. Clin. Oncol."},{"key":"95844_CR23","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.clon.2018.06.004","volume":"30","author":"S Parikh","year":"2018","unstructured":"Parikh, S. et al. Real-world outcomes and factors predicting survival and completion of radium 223 in metastatic Castrate-resistant prostate cancer. Clin. Oncol. (R Coll. Radiol). 30, 548\u2013555. https:\/\/doi.org\/10.1016\/j.clon.2018.06.004 (2018).","journal-title":"Clin. Oncol. (R Coll. Radiol)"},{"key":"95844_CR24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.urolonc.2021.11.005","volume":"40","author":"D Sasaki","year":"2022","unstructured":"Sasaki, D. et al. Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study. Urol. Oncol. 40, e61\u2013e64 (2022).","journal-title":"Urol. Oncol."},{"key":"95844_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaf007","author":"F Urabe","year":"2025","unstructured":"Urabe, F. et al. Evaluation of optimal timing and therapeutic efficacy of radium-223 therapy for metastatic castration-resistant prostate cancer: A multicenter collaborative study. Jpn. J. Clin. Oncol. https:\/\/doi.org\/10.1093\/jjco\/hyaf007 (2025).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"95844_CR26","unstructured":"EMA restricts use of prostate cancer medicine Xofigo. https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/ema-restricts-use-prostate-cancer-medicine-xofigo_en.pdf  (2018)."},{"key":"95844_CR27","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/cas.14722","volume":"112","author":"M Shiota","year":"2021","unstructured":"Shiota, M. et al. Differential prognostic factors in low- and high-burden de Novo metastatic hormone-sensitive prostate cancer patients. Cancer Sci. 112, 1524\u20131533. https:\/\/doi.org\/10.1111\/cas.14722 (2021).","journal-title":"Cancer Sci."},{"key":"95844_CR28","doi-asserted-by":"publisher","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2307","volume":"35","author":"S Gillessen","year":"2024","unstructured":"Gillessen, S. et al. LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333\/PEACE-3. Ann. Oncol. 35, S1254. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2307 (2024).","journal-title":"Ann. Oncol."},{"key":"95844_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/iju.15097","volume":"30","author":"N Terada","year":"2023","unstructured":"Terada, N. et al. The efficacy of sequential therapy with docetaxel and Cabazitaxel for castration-resistant prostate cancer: A retrospective multi-institutional study in Japan. Int. J. Urol. 30, 227\u2013234. https:\/\/doi.org\/10.1111\/iju.15097 (2023).","journal-title":"Int. J. Urol."},{"key":"95844_CR30","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/iju.15243","volume":"30","author":"X Yang","year":"2023","unstructured":"Yang, X. et al. Far from the truth: Real-world treatment patterns among newly diagnosed metastatic prostate cancer in the era of treatment intensification. Int. J. Urol. 30, 991\u2013999. https:\/\/doi.org\/10.1111\/iju.15243 (2023).","journal-title":"Int. J. Urol."},{"key":"95844_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15550","author":"H Miura","year":"2024","unstructured":"Miura, H. et al. Treatment trends in patients with de Novo metastatic prostate cancer in the era of upfront combination therapy. Int. J. Urol. https:\/\/doi.org\/10.1111\/iju.15550 (2024).","journal-title":"Int. J. Urol."},{"key":"95844_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15657","author":"W Chen","year":"2024","unstructured":"Chen, W. et al. Efficacy of docetaxel addition to next-generation androgen receptor-axis-targeted therapies and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: A tumor volume-specific analysis. Int. J. Urol. https:\/\/doi.org\/10.1111\/iju.15657 (2024).","journal-title":"Int. J. Urol."},{"key":"95844_CR33","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10147-024-02670-5","volume":"30","author":"M Taga","year":"2025","unstructured":"Taga, M. et al. Efficacy of androgen receptor signaling inhibitors in combination with androgen deprivation therapy for castration-sensitive metastatic prostate cancer: A retrospective analysis in a Japanese cohort. Int. J. Clin. Oncol. 30, 351\u2013357. https:\/\/doi.org\/10.1007\/s10147-024-02670-5 (2025).","journal-title":"Int. J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95844-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95844-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95844-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T13:48:58Z","timestamp":1743256138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95844-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["95844"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-95844-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"8 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shingo Hatakeyama received honoraria from Janssen Pharmaceutical K.K., Astellas Pharma Inc., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Bayer AG, Pfizer Inc., Bristol-Myers Squibb, Merck Biopharma Co., Ltd., Kaneka Corporation, and Nipro Corporation. Other authors have no conflicts of interest to declare. Other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors approved for the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Written consent was not obtained in exchange for the public disclosure of study information (opt-out approach).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"10814"}}